Search
sunitinib (Sutent)
Indications:
- treatment of renal cell carcinoma
- adults at risk for recurrent renal cell carcinoma following nephrectomy [8]
- treatment of imatinib-resistant gastrointestinal stromal tumor
- treatment of hepatocellular carcinoma [6]
- islet cell tumor [7]
Dosage:
- 50 mg PO QD for 4 weeks followed by 2 week drug holiday
Capsules: 12.5 mg, 25 mg or 50 mg
Drug interactions:
- several reports of microangiopathic hemolytic anemia in patients with solid tumors receiving Avastin in combination with sunitinib malate; this combination is not recommended [2]
Adverse effects:
- cardiovascular events
- skin & tissue problems (rash), hands, feet [6]
- gastrointestinal events
- hemorrhage
- hypertension
- hematological problems
- venous thromboembolism
- pulmonary embolism
- thrombotic microangiopathy
- hypothyroidism
Laboratory:
- thyroid function testing
Mechanism of action:
- tyrosine kinase inhibitor
- inhibits CSF1R, VEGF receptor, PDGF receptor, raf [6]
Interactions
drug adverse effects of tyrosine kinase inhibitor(s)
General
antineoplastic tyrosine kinase inhibitor
References
- Prescriber's Letter 14(2): 2007
New drugs approved by the FDA in 2006
Detail-Document#: 2302213
(subscription needed) http://www.prescribersletter.com
- FDA Medwatch
http://www.fda.gov/medwatch/safety/2008/safety08.htm#Avastin
- Sutent
http://www.sutent.com/
- National Cancer Institute: Sunitinib Malate
http://www.cancer.gov/cancertopics/druginfo/sunitinibmalate
- Wikipedia: Sunitinib
http://en.wikipedia.org/wiki/Sunitinib
- RxList
Sutent
http://www.rxlist.com/sutent-drug.htm
- Medical Knowledge Self Assessment Program (MKSAP) 16, 17
American College of Physicians, Philadelphia 2012, 2015
- Deprecated Reference
- FDA News Release. November 16, 2017
FDA expands approval of Sutent to reduce the risk of kidney cancer
returning.
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm585657.htm